Congenital hyperinsulinemia, a rare hereditary disease, has been included in the First List of Rare Diseases in China. However, there is still no safe and effective drug for congenital hyperinsulinemia in China.

PB-722 is a long-acting glucagon receptor agonist for the treatment of congenital hyperinsulinemia and has been granted orphan drug designation by the FDA. The drug has been proved to be safe in multiple animal models and has been confirmed to be effective in elevating and maintaining blood glucose levels in the animal model of hypoglycemia.